CSL Behring
1020 First Avenue
King of Prussia
Pennsylvania
19406
United States
Tel: 610-878-4000
Fax: 610-878-4009
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
348 articles about CSL Behring
-
Perreault Will Move Up to CEO of CSL Behring
8/6/2012
-
CSL Behring Awards Advocacy Grants to Patient Groups in Six States: NC, CA, WA, PA, IL, NY
8/2/2012
-
CSL Behring Release: World's First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment
7/12/2012
-
CSL Behring Release: PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6/27/2012
-
CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
6/8/2012
-
CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5/29/2012
-
CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
5/7/2012
-
CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
5/4/2012
-
CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
4/17/2012
-
CSL Behring Commences Phase I Study With rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors
4/2/2012
-
CSL Behring Release: Findings Confirm Benefits of Albumin in Treating Cirrhosis Patients Undergoing Large-Volume Paracentesis
3/29/2012
-
First Patient Enrolled in CSL Behring PATH Trial to Evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra(R), in the Treatment of CIDP
3/27/2012
-
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
3/16/2012
-
CSL Behring Study Confirms Early Treatment with Berinert(R) Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3/7/2012
-
CSL Behring Release: Analysis Finds Bioavailability of IgG is Consistent, Regardless of Formulation
3/5/2012
-
CSL Behring Recognized as a "Pioneer" By European Organization for Rare Diseases (EURORDIS)
3/1/2012
-
First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2/27/2012
-
Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management
2/21/2012
-
CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
2/16/2012
-
CSL Behring Announces 2012 Interlaken Leadership Awards Recipients
2/15/2012